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Taking the Stem Cell Debate to the Public
I
n their essay in the April 2004 issue 
of PLoS Biology, Elizabeth Blackburn 
and Janet Rowley (2004), two 
distinguished cellular biologists and 
members of the President’s Council 
on Bioethics, strongly question the 
scientiﬁ  c foundation of two reports 
from the Council (President’s Council 
on Bioethics 2003, 2004). The Council 
on Bioethics was formed by executive 
order “to advise the President on 
bioethical issues that may emerge 
as a consequence of advances in 
biomedical science and technology.” 
An open discussion between ethicists 
and scientists is critical to the advisory 
system. The recent administrative 
dismissal of Dr. Blackburn from the 
Council is very alarming. By stacking 
the deck with conservative opinions, 
and not accurately discussing the 
scientiﬁ  c issues, the Bioethics Council 
has become irrelevant to the scientiﬁ  c 
community and presents a jaundiced 
view to the public. 
Stem cell research and its 
applications have the potential to 
revolutionize human health care. 
Recent polls show support for 
embryonic stem cell research, even 
with conservative voters. The public, 
as the major benefactor of biomedical 
research and the target population 
of beneﬁ  cial clinical advances, has 
the right to a fact-based discussion of 
the science regarding stem cells. It is 
therefore time that the debate on stem 
cell research, with its risks and beneﬁ  ts, 
be taken to the public. A debate on 
stem cell research restricted to the 
President’s Council on Bioethics is a 
disservice to the public.
Nearly three decades ago, the advent 
of recombinant DNA technology and 
in vitro fertilization (IVF) techniques, 
raised similar concerns regarding 
research. Contrary to apprehensive 
expectations, recombinant DNA 
technology has boosted enormous 
advances in the health care and 
pharmaceutical industry. IVF evolved 
to be a widely accepted, safe medical 
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procedure, with over one million 
healthy babies born by IVF and related 
treatments. Similarly, once stem cells 
are successfully used in the clinic, most 
of today’s political and ethical issues 
will evaporate.
The International Society for Stem 
Cell Research (ISSCR), a society whose 
membership encompasses the bulk 
of the stem cell research brain trust, 
holds the position that research on 
both adult and embryonic stem cells 
will guarantee the fastest progress 
in scientiﬁ  c discovery and clinical 
advances. The ISSCR also strongly 
opposes reproductive cloning and 
supports the National Academy of 
Science’s proposal to develop voluntary 
guidelines to encourage responsible 
practices in human embryonic stem cell 
research. 
One of the original recommen-
dations of the President’s Council on 
Bioethics was a four-year moratorium 
on stem cell research. The purpose 
of this moratorium was theoretically 
to open a large, national discourse 
on the topic of stem cell research, a 
debate intended to bring all sides into 
thoughtful reﬂ  ection on the issue. To 
that end, the ISSCR has repeatedly 
and consistently offered an open 
forum for all sides in the debate at 
our conferences, and has carefully 
offered invitations to join our society 
and to speak at our annual meeting to 
members of the President’s Council, 
including colleagues whose opposition 
to stem cell research has been clear. 
None have accepted. Dr. Kass, in 
particular, has received several direct 
appeals but has turned down every 
such opportunity to make his case 
to the researchers who arguably are 
his discourse partners, from whom 
he could learn much, and whom he 
should be actively engaged in teaching. 
It is tragic that voices of dissent and 
debate are stilled, for it is this very 
quality of open debate that is at the 
heart of both the scientiﬁ  c method 
and an ethically directed American 
democracy—surely a goal that we all 
share.  
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Beyond Therapy …
I
t is indeed regrettable that a 
distinguished and thoughtful 
scientist such as Elizabeth 
Blackburn should have been dismissed 
from the President’s Council on 
Bioethics. Scientiﬁ  c perspectives such 
as hers are surely needed on this 
committee.
Her dismissal was apparently the 
consequence of her disagreement 
with some of the text of the 
Council’s report, “Beyond Therapy: 
Biotechnology and the Pursuit of 
Happiness” (2003). The thrust of this 
report is that some of the directions 
of current biological research will, if 
carried to fulﬁ  llment, result in major 
changes in the nature of human life—
changes that the report regards with 
foreboding.  
In their essay, Drs. Blackburn and 
Rowley (2004) try to bypass these 
concerns with the argument that we 
really are not able to accomplish any 
of these changes yet and, indeed, some 
may never be possible.
I would suggest that as scientists we 
should face these issues forthrightly.  
We should not seek refuge in present-
day uncertainties. The authors of the 
report are not naïve nor ignorant. Yes, 
if these lines of research are successful, 
their outcome will change the nature of 
human life.
As an example, consider current 
research into the causes of aging. 
Clearly, we do not at present know 
how to achieve major increases in the 
human life span (although we are able 
to do so in lower life forms). But it is 
plausible that we will learn how to do 
so. And surely a, say, doubling of the 
human life span would change the 
nature of human life.  
Likewise, if we learn to modify the 
human gene pool so as to produce 
exceptional individuals or to alter 
human capabilities, or if powerful 
drugs are developed  that may 
commandeer the human psyche, the 
nature of human life will be  altered. 
But so be it. The nature of 
human life has changed repeatedly 
and profoundly in the past—with 
the invention of agriculture, with 
the invention of writing, with the 
development of machines and 
mechanical power, with the advent of 
modern science and medicine. The 
nature of human life is different in 
2004 a.d. from what it was in 1000 a.d. 
or 46 b.c. or 5000 b.c. or 10,000 b.c., 
and it will change again in the future.  
The concerns expressed in the 
report are earnest, and they should be 
confronted in earnest.  
Robert Sinsheimer
Department of Molecular, Cellular, and Developmen-
tal Biology, University of California at Santa Barbara, 
Santa Barbara, California, United States 
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Ethics as Our Guide
B
lackburn and Rowley’s (2004) 
criticism of a report on 
embryonic stem cell research 
from the President’s Council on 
Bioethics (2004) is puzzling. Where 
is the bioethics? The nub of their 
complaint is that some details of the 
report have been partisan and have 
distorted ‘the potential of biomedical 
research and the motivation of some 
of its researchers’. No doubt their 
quibbles are well-founded, as every 
committee report is a compromise. 
However, it does not follow that 
if the beneﬁ  ts of embryo stem cell 
research had been presented more 
persuasively and in greater detail, 
then the case for ‘non-commercial, 
federal, peer-reviewed funding’ would 
be unassailable. Such a view appears 
to be based squarely on a utilitarian 
view of the moral status of embryos: 
that the good ﬂ  owing from destructive 
research outweighs the evil of embryo 
destruction. Far from being a neutral 
scientiﬁ  c analysis, this expresses a 
commitment to the proposition that 
biomedical progress is more important 
than the defence of human life. 
If twentieth century philosophy 
of science has taught us anything, 
it is that the aspiration to pure 
scientiﬁ  c objectivity is a dangerous 
illusion. Research programs always 
embody philosophical and moral 
assumptions that must be openly 
defended. If Blackburn and Rowley 
want government support for embryo 
stem cell research, they must justify 
their bioethical approach and not hide 
behind a smokescreen of indignation 
over Blackburn’s unwilling departure 
from the Council.  
Michael Cook
BioEdge, Australasian Bioethics Information, Sandy 
Bay, Tasmania, Australia
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Scientists and Bioethics Councils
I 
read with interest the article in 
a recent issue of PLoS Biology by 
Elizabeth Blackburn and Janet 
Rowley, two of the scientiﬁ  c members 
of President Bush’s Council on 
Bioethics. Invited by the President to 
serve on this Council, they say that it 
was ‘a difﬁ  cult invitation to accept’. 
Maybe, but that they did accept the 
invitation is to be applauded. As the 
Council’s report ‘Monitoring Stem Cell 
Research’ states, ‘fairness in ethical 
evaluation and judgment depends 
on … fair and accurate description 
of the relevant facts of the case at 
hand’. In other (fewer) words, sound 
ethics requires a solid base in sound 
science. It is crucial that any bioethics 
committee or council made up of ten 
to twenty members should include at 
least two or three scientists broadly 
acquainted with the ﬁ  eld in general, 
and with recent published ﬁ  ndings. I 
was only sorry to read that Elizabeth 
Blackburn (who works in California 
but is a Fellow of the Royal Society, the 
United Kingdom Academy of Sciences) 
had her Council term terminated by 
White House directive on February 27, 
2004.
Of course, any bioethics committee 
or council (and I have served on several 
such, both in the UK and elsewhere 
in Europe) is likely also to include 
philosophers, lawyers, theologians, 
sociologists, and probably ‘lay’ people 
of appropriate interests. The scientists 
may well ﬁ  nd that other members 
of the group have ‘strong opposing 
views’ on ethical issues, as well as on 
the costs and beneﬁ  ts of technologies 
arising from biomedical research. 
Elizabeth Blackburn and Janet Rowley 
were assured, both by Leon Kass, 
the chairman of the Council, and by 
President Bush himself, that their 
voices would be heard and integrated 
into the Council statements. It is 
therefore disappointing to learn that, 
in the ‘Beyond Therapy’ report (which 
I have not yet read), their requests for 
revision of certain aspects was declined. 
Were they not offered the option of 
a brief minority report? It would be 
expected in such circumstances that 
dissenting opinions would be recorded 
(as was done, for example, in the 
1984 UK report by the Committee on 
Human Fertilisation and Embryology 
chaired by Mary Warnock (1984), and 
in some of the Opinions offered by 
the European Group of Ethics to the 
European Commission). This would be 
particularly appropriate, and indeed 
essential, when recommendations are 
put forward.
The ‘Monitoring Stem Cells 
Research’ report (which I have read) 
contains no recommendations, but 
includes a rather comprehensive 
survey of the various ethical positions 
relating to human embryonic stem cell 
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research, a historical account of the 
development up to the present time of 
federal law and policy, and a chapter 
on recent (almost entirely United 
States) developments in human stem 
cell research and therapy. The scientists 
must have contributed substantially to 
this section of the report. Emphasis 
is put on the need for research on 
both adult and embryonic stem cells, 
since at present there is no way to 
assess which approach has the more 
promising therapeutic potential for 
which diseases. Some funding ﬁ  gures 
are given: on human embryonic stem 
cell research the US National Institutes 
of Health spent $10.7 million in 2002 
and $17 million in 2003, with an 
estimated total spent by US companies 
of $70 million, while in the same 
two years the National Institutes of 
Health spent $170 million in 2002 
and $181.5 million in 2003 on adult 
stem cell research. However, it is not 
obvious that there are any US scientists 
wanting to work on human embryonic 
stem cells within the constraints of US 
federal funding who are prevented 
from doing so by lack of money.
To my mind, the major deﬁ  ciency in 
the ‘Monitoring Stem Cells Research’ 
report is the almost complete lack of 
reference to what Elizabeth Blackburn 
and Janet Rowley correctly call ‘years 
of rigorous and careful research in 
animal models’. Some mention is made 
of experiments with human embryonic 
stem cells in immunologically 
handicapped mice, but in any such 
model both the stem cells and the mice 
are difﬁ  cult to work with. Much of the 
science-based optimism that human 
embryonic stem cells may eventually 
prove of therapeutic value springs 
from the results of experiments with 
mouse embryonic stem cells in intact 
mice. Curiously, only a single such 
experiment is cited: an impressive but 
somewhat recondite piece of work from 
Jaenisch’s laboratory (Rideout et al. 
2002), using cloned and genetically 
modiﬁ  ed mouse embryonic stem cells 
to treat a form of mouse hepatitis. A 
wider consideration of work on animal 
models, together with some emphasis 
on the potential use of human 
embryonic stem cells for toxicity testing 
and drug design by pharmaceutical 
companies, is in part what Elizabeth 
Blackburn and Janet Rowley believe 
‘would help the public and scientists 
better assess the content of the report’. 
If they requested inclusion of such 
material, it is unfortunate that their 
requests were declined.  
Anne McLaren
Wellcome Trust/Cancer Research UK Gurdon Institute, 
Cambridge University, Cambridge, United Kingdom
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A Voice for Research, a Voice for Patients
I
n the very thoughtful essay “Reason 
as Our Guide” by Drs. Elizabeth 
Blackburn and Janet Rowley (2004), 
the authors highlight a key concern 
with the reports published by the 
President’s Council on Bioethics—the 
lack of credible scientiﬁ  c information 
being passed on to policy makers. 
Blackburn and Rowley point out 
many areas of the report “Monitoring 
Stem Cell Research” that needed 
correction from a scientiﬁ  c standpoint.  
While it is impossible to include every 
suggestion in a report that seeks to 
draw consensus from a large panel of 
members, in a heated, political debate 
like that surrounding embryonic 
stem cell research and therapeutic 
cloning, providing the most accurate 
and complete scientiﬁ  c information to 
policy makers is crucial.  Unfortunately, 
with the recent dismissal of Dr. 
Blackburn from the Council, there 
will now be one less voice for scientiﬁ  c 
research and for the potential the 
research holds for curing disease and 
alleviating the suffering of millions.  
Speaking for the Coalition for the 
Advancement of Medical Research, our 
concern is not only the small number 
of researchers on the Council and 
lack of complete scientiﬁ  c data being 
shared with policy makers, but the 
absence of patient representation on 
the Council itself.  With the exception 
of public comment periods, patient 
organizations have no voice in the work 
of the Council as it discusses issues 
that profoundly impact them.  Now, 
with one less member standing up for 
research and thus patients, our concern 
grows even stronger.  
The Blackburn and Rowley essay 
also correctly points out that there is 
more published work on adult stem 
cell research because of a “paucity of 
funding for research using embryonic 
stem cells.” Despite this lack of federal 
and private funding, advances continue 
to be made—but just think of the 
advances we could have had if only 
there were a supportive federal policy 
that encouraged embryonic stem cell 
research instead of stiﬂ  ing it.  We 
hope—in light of scientiﬁ  c advances 
made over the past several years and 
the strong support of the scientiﬁ  c 
community, including the National 
Institutes of Health, the Health and 
Copyright: © 2004 Daniel Perry. This is an open-
access article distributed under the terms of the 
Creative Commons Attribution License, which 
permits unrestricted use, distribution, and reproduc-
tion in any medium, provided the original work is 
properly cited. 
E-mail: camresearch@yahoo.com
DOI: 10.1371/journal.pbio.0020182June 2004  |  Volume 2  |  Issue 6  |  Page 0739 PLoS Biology  |  http://biology.plosjournals.org
Human Services Department, and the 
National Academy of Sciences—that 
the President will reevaluate the 
current federal policy for stem cell 
research and consider easing the 
restrictions.
We commend Drs. Blackburn and 
Rowley for trying to set the record 
straight in their essay, and applaud 
their efforts to stand up for medical 
research, which has the potential to 
beneﬁ  t us all.  
Daniel Perry
Coalition for the Advancement of Medical Research, 
Washington, District of Columbia, United States of 
America
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Ethereal Ethics
I
t is a great pity when vested 
interest and dogma dominate what 
should be a well-informed and 
rational debate. The essay by Elizabeth 
Blackburn and Janet Rowley (2004), 
about the output and the workings of 
the President’s Council on Bioethics, 
therefore prompted in me a strong 
reaction of sadness and despair, 
although I have to admit not one of 
surprise. 
In the United Kingdom, we have 
had an almost continuous debate since 
the mid 1980s on topics relating to 
research on early human embryos. I 
myself have been involved in some of 
this debate, especially over the last few 
years, relating to human embryonic 
stem cells and nuclear transfer. I will 
not dwell on the political outcomes of 
this debate, which are widely known, 
but I want to stress that it has been 
one that has been very well informed, 
with contributions from all sides, 
including many highly respected moral 
philosophers and bioethicists. These 
include notable individuals such as 
Dame Mary Warnock and bodies such 
as the Nufﬁ  eld Bioethics Council, who 
have been especially valuable because 
of their independence. 
So why are the conclusions reached 
by bioethicists in the UK, who are 
generally supportive of research 
involving human embryos, different 
from those of the President’s Council 
on Bioethics? The same scientiﬁ  c 
information is available on both sides 
of the Atlantic. The rules of logic are 
the same. So it has to be the way the 
information is interpreted or ﬁ  ltered. 
This implies bias or vested interest or 
the input of dogma that is based on 
belief rather than rational thought. 
Some examples of this are discussed 
in the Blackburn and Rowley essay, 
and they are very worrying. The scare 
mongering about preimplantation 
genetic diagnosis is ridiculous—simple 
mathematics shows that it is implausible 
to use this technique to screen the 
usual number of embryos obtained in 
one round of in vitro fertilisation for 
more than two or three genetic traits, 
while we know that intelligence must 
rely on many more. I am a great fan of 
science ﬁ  ction, but I can recognise it 
as such. I worry that some members of 
the President’s Council seem unable to 
do this. Many of these daft ideas were 
already promoted in a book by Francis 
Fukuyama (2002), and while they 
can be a harmless way of promoting 
debate, they should not be included 
in documents meant to inform policy 
makers. 
It is certainly very unfortunate if the 
input of real science in the Council is 
to be reduced. The scientiﬁ  c issues are 
complex. For example, we certainly do 
not know nearly enough about either 
adult or embryonic stem cells to say 
which will be the best for therapies, 
and of course it is possible that both 
will turn out to be useful for different 
problems. Both also offer exciting new 
ways to explore human disease and the 
inﬂ  uence of genetics and environment 
without having to rely on human 
experimentation. But any committee 
looking into what is ethically acceptable 
has to be provided with a balanced 
view of what will be possible in the near 
future. There is no point in being too 
speculative, in part because it is also 
difﬁ  cult to predict what will be ethically 
acceptable in the future. If cures come 
from the use of human embryonic stem 
cells, then I suspect that there will be 
widespread acceptance, as happened 
with heart transplants and with in vitro 
fertilisation, both of which were initially 
greeted with horror by many. 
It is impossible to have an informed 
debate without accurate and 
appropriate information, and there 
seems little point in having a debate 
that is not informed. Because of various 
sensitivities, it seemed to me before the 
creation of the President’s Council on 
Bioethics that for far too long the issues 
relating to embryo research had not 
been considered properly within the 
United States. The President’s Council 
was therefore an opportunity to redress 
this situation. But from the evidence 
I fear it will not succeed. Moreover, it 
does the general public a disservice to 
pretend to have a serious committee 
exploring issues of bioethics when that 
committee fails to live up to the ideals 
of impartiality and rationality.  
Robin Lovell-Badge
Division of Developmental Genetics, Medical 
Research Council National Institute for Medical 
Research, London, United Kingdom
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